Please ensure Javascript is enabled for purposes of website accessibility

Why Furiex Pharmaceuticals Inc. Is an Instant Double

By Dave Williamson - Feb 4, 2014 at 5:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Furiex pulls the classic biotech instant double. How should investors play this fast-moving stock?

Shares of Furiex Pharmaceuticals (NASDAQ: FURX) exploded today, up 145% as the company released data that its drug treating a form of IBS that results in diarrhea passed its phase 3 trials, soundly beating a placebo at the higher dosing.

In this video, Motley Fool health-care analyst David Williamson discusses whether or not he thinks the drug will be approved and what the potential market size could be, and looks at just how high this stock could go.

David Williamson owns shares of AbbVie. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.14 (0.00%) $0.00
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$141.52 (0.41%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.